Overview

Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg topiramate tablets following a 50 mg dose under fasting conditions.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Topiramate